Recruiting EARLY_PHASE1 INTERVENTIONAL 3-arm NCT06989853

Methamphetamine and Troriluzole (BED IN 46)

Advancing Troiluzole as a Treatment for Methamphetamine Use Disorder: A Human Laboratory Study

Sponsor: National Institute on Drug Abuse (NIDA)

Updated 5 times since 2025 Last updated: Dec 20, 2025 Started: Aug 25, 2025 Primary completion: Feb 28, 2029 Completion: Feb 28, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This EARLY_PHASE1 trial investigates Methamphetamine Use Disorder and is currently actively recruiting participants. National Institute on Drug Abuse (NIDA) leads this study, which shows 5 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Jan 2026 — Present [monthly]

Recruiting EARLY_PHASE1
Oct 2025 — Jan 2026 [monthly]

Recruiting EARLY_PHASE1
Sep 2025 — Oct 2025 [monthly]

Recruiting EARLY_PHASE1
Aug 2025 — Sep 2025 [monthly]

Recruiting EARLY_PHASE1

Status: Not Yet Recruiting → Recruiting
Jun 2025 — Aug 2025 [monthly]

Not Yet Recruiting EARLY_PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute on Drug Abuse (NIDA)
William Stoops

Data source: University of Kentucky

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lexington, United States